Display options
Cite
Namiki M, Ueno S, Kitagawa Y. Role of hormonal therapy for prostate cancer: perspective from Japanese experiences. Transl Androl Urol. 2012;1(3):160-72doi: 10.3978/j.issn.2223-4683.2012.07.03.
Namiki, M., Ueno, S., & Kitagawa, Y. (2012). Role of hormonal therapy for prostate cancer: perspective from Japanese experiences. Translational andrology and urology, 1(3), 160-72. https://doi.org/10.3978/j.issn.2223-4683.2012.07.03
Namiki, Mikio, et al. "Role of hormonal therapy for prostate cancer: perspective from Japanese experiences." Translational andrology and urology vol. 1,3 (2012): 160-72. doi: https://doi.org/10.3978/j.issn.2223-4683.2012.07.03
Namiki M, Ueno S, Kitagawa Y. Role of hormonal therapy for prostate cancer: perspective from Japanese experiences. Transl Androl Urol. 2012 Sep;1(3):160-72. doi: 10.3978/j.issn.2223-4683.2012.07.03. PMID: 26813083; PMCID: PMC4708248.
Copy Download .nbib Format: NLM
Share it on

Transl Androl Urol. 2012 Sep;1(3):160-72. doi: 10.3978/j.issn.2223-4683.2012.07.03.

Role of hormonal therapy for prostate cancer: perspective from Japanese experiences.

Translational andrology and urology

Mikio Namiki, Satoru Ueno, Yasuhide Kitagawa

Affiliations

  1. Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan.

PMID: 26813083 PMCID: PMC4708248 DOI: 10.3978/j.issn.2223-4683.2012.07.03

Abstract

Hormonal therapy has been playing an important role in the treatment of prostate cancer. However, it has recently been the subject of criticism that it shows minimal effectiveness, it may reduce patients' quality of life, and induce adverse effects. On the other hand, next-generation hormonal drugs have provided new strategies for hormonal therapy to overcome advanced prostate cancer. Therefore, it is necessary to accumulate further clinical evidence concerning the efficacy and adverse effects of hormonal therapy. And, what is important for the treatment of prostate cancer is how we use hormonal therapy most effectively. This article presents a review of the possible roles of hormonal therapy for prostate cancer based upon experience in Japan.

Keywords: Adverse effects; hormonal therapy; prostate cancer

References

  1. Cancer. 2003 Apr 1;97(7):1653-62 - PubMed
  2. Int J Radiat Oncol Biol Phys. 1997 Jul 15;38(5):1071-7 - PubMed
  3. Cancer Res. 2006 Mar 1;66(5):2815-25 - PubMed
  4. J Clin Oncol. 2009 Aug 10;27(23 ):3742-8 - PubMed
  5. Lancet. 2002 Jul 13;360(9327):103-6 - PubMed
  6. Int J Urol. 2004 May;11(5):304-9 - PubMed
  7. Pharmacology. 2010;85(2):110-20 - PubMed
  8. Lancet. 2009 Jan 24;373(9660):301-8 - PubMed
  9. J Clin Invest. 2010 Aug;120(8):2715-30 - PubMed
  10. Clin Cancer Res. 2010 Sep 1;16(17 ):4319-24 - PubMed
  11. Int J Radiat Oncol Biol Phys. 1999 Jul 1;44(4):789-99 - PubMed
  12. BJU Int. 2007 Jan;99 Suppl 1:6-9; discussion 17-8 - PubMed
  13. Int J Urol. 2006 Dec;13(12):1494-500 - PubMed
  14. J Clin Oncol. 2011 May 20;29(15):2040-5 - PubMed
  15. J Clin Oncol. 2007 Jun 10;25(17):2420-5 - PubMed
  16. Eur Urol. 2000 Dec;38(6):706-13 - PubMed
  17. Science. 2009 May 8;324(5928):787-90 - PubMed
  18. Biochem Biophys Res Commun. 1988 Dec 15;157(2):705-12 - PubMed
  19. Int J Radiat Oncol Biol Phys. 2004 Aug 1;59(5):1352-9 - PubMed
  20. N Engl J Med. 2009 Jun 11;360(24):2516-27 - PubMed
  21. BJU Int. 2006 Jun;97(6):1190-3 - PubMed
  22. Steroids. 1997 Jan;62(1):148-58 - PubMed
  23. Int J Urol. 2007 May;14(5):416-21 - PubMed
  24. J Urol. 2002 Jul;168(1):9-12 - PubMed
  25. Proc Natl Acad Sci U S A. 2010 Sep 28;107(39):16759-65 - PubMed
  26. Lancet Oncol. 2006 Jun;7(6):472-9 - PubMed
  27. BJU Int. 2006 Sep;98(3):573-9 - PubMed
  28. J Clin Oncol. 2010 Mar 20;28(9):1496-501 - PubMed
  29. Nat Clin Pract Urol. 2008 Dec;5(12):648-9 - PubMed
  30. J Urol. 2005 Jun;173(6):1947-52 - PubMed
  31. J Clin Oncol. 2009 May 1;27(13):2137-43 - PubMed
  32. Int J Radiat Oncol Biol Phys. 1997 Jan 15;37(2):245-6 - PubMed
  33. Urology. 2009 Jun;73(6):1342-6 - PubMed
  34. J Clin Oncol. 2008 May 20;26(15):2497-504 - PubMed
  35. Psychooncology. 2002 Sep-Oct;11(5):401-14 - PubMed
  36. JAMA. 2004 Aug 18;292(7):821-7 - PubMed
  37. JAMA. 2008 Jul 9;300(2):173-81 - PubMed
  38. J Biol Chem. 2012 Feb 3;287(6):3777-87 - PubMed
  39. J Urol. 2011 May;185(5):1674-80 - PubMed
  40. Cancer. 2006 Feb 1;106(3):581-8 - PubMed
  41. Oncology (Williston Park). 2008 Aug;22(9):995-1004; discussion 1006, 1011-7 - PubMed
  42. Mol Endocrinol. 1991 Oct;5(10 ):1373-80 - PubMed
  43. Endocr Rev. 2005 May;26(3):361-79 - PubMed
  44. Cancer Res. 2004 Jan 15;64(2):765-71 - PubMed
  45. J Biol Chem. 1993 Aug 25;268(24):18267-71 - PubMed
  46. Int J Urol. 2010 Apr;17(4):337-45 - PubMed
  47. Int J Urol. 2005 Jan;12(1):46-61 - PubMed
  48. Nat Rev Clin Oncol. 2011 Jan;8(1):12-23 - PubMed
  49. J Clin Oncol. 2009 Jan 1;27(1):92-9 - PubMed
  50. BMC Cancer. 2012 Mar 22;12:110 - PubMed
  51. Lancet. 2010 Apr 24;375(9724):1437-46 - PubMed
  52. J Natl Cancer Inst. 2003 Jul 2;95(13):981-9 - PubMed
  53. Int J Urol. 2003 Jul;10(7):377-82 - PubMed
  54. Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1243-52 - PubMed
  55. Anticancer Res. 2010 Dec;30(12):5201-5 - PubMed
  56. Cancer. 2006 Sep 15;107(6):1265-72 - PubMed
  57. J Clin Oncol. 2006 Sep 20;24(27):4448-56 - PubMed
  58. Cancer. 2009 Aug 1;115(15):3437-45 - PubMed
  59. Endocrinology. 2009 Dec;150(12):5606-16 - PubMed
  60. Urology. 2002 Jul;60(1):115-9 - PubMed
  61. Nihon Rinsho. 2000 Jul;58 Suppl:289-91 - PubMed
  62. Neoplasia. 2012 Jan;14(1):74-83 - PubMed
  63. JAMA. 1998 Sep 16;280(11):969-74 - PubMed
  64. J Urol. 2008 Sep;180(3):921-7 - PubMed

Publication Types